Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03

被引：0
|
作者：
Saura, Cristina
Cortes, Javier
Modi, Shanu
Kim, Sung-Bae
Hamilton, Erika P.
Hurvitz, Sara A.
Krop, Ian E.
Curigliano, Giuseppe
Iwata, Hiroji
Im, Seock-Ah
Herbolsheimer, Pia Maarit
Karnoub, Maha
Gambhire, Dhiraj
Egorov, Anton
Andre, Fabrice
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Quironsalud Grp, Int Breast Canc Ctr IBCC, Pangaea Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Univ Washington, Sch Med, Seattle, WA USA
[7] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[8] Yale Canc Ctr, New Haven, CT USA
[9] Univ Milan, Milan, Italy
[10] IRCCS, European Inst Oncol, Milan, Italy
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst,Natl Univ Hosp, Seoul, South Korea
[13] AstraZeneca, Gaithersburg, MD USA
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Daiichi Sankyo, Basking Ridge, NJ USA
[16] Univ Paris Saclay, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1023
引用
收藏
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER
    Mudumba, R.
    Chan, H.
    Cheng, Y. Y.
    Wang, C. C.
    Correia, L.
    Ballreich, J.
    Levy, J.
    VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
  • [32] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
    Li, B. T.
    Planchard, D.
    Goto, K.
    Smit, E. F.
    De langen, J.
    Goto, Y.
    Ninomiya, K.
    Kubo, T.
    Perol, M.
    Felip, E.
    Hayashi, H.
    Nakagawa, K.
    Shimizu, J.
    Nagasaka, M.
    Pereira, K. M. C.
    Taguchi, A.
    Ali, A.
    Karnoub, M.
    Yonemochi, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [33] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)
    Oh, Do-Youn
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jung, Kyung Hae
    Dumas, Olivier
    Penkov, Konstantin
    Dechaphunkul, Arunee
    Oaknin, Ana
    Kim, Seung Tae
    Starling, Naureen
    Chewaskulyong, Busyamas
    Charonpongsuntorn, Chanchai
    Doroshow, Deborah Blythe
    Hsiao, Sheng-Yen
    Hung, Yi-Ping
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Michelini, Flavia
    Puvvada, Soham D.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Saura, Cristina
    Yamashita, Toshinari
    Kim, Sung-Bae
    Tamura, Kenji
    Chen, Shuquan
    Suto, Fumitaka
    Kuwahara, Yusuke
    Lee, Caleb C.
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)
    Tripathy, Debashish
    Ali, Kashif
    Agrawal, Laila
    Ali, Sami M.
    Blau, Sibel
    Block, Margaret
    Danso, Michael A.
    Yardley, Denise
    Andersen, Jay
    Waks, Adrienne Gropper
    Jayachandran, Priya
    Makhlin, Igor
    Nikolinakos, Petros
    Zuniga, Richard
    O'Shaughnessy, Joyce
    Aung, Sandra
    Lu, Janice M.
    Kalinsky, Kevin
    Gradishar, William John
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Whole exome sequencing (WES) in HER2+metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T)
    Luis, Ines Maria Vaz Duarte
    Oh, Coyin
    Wang, Zhigang
    Dipiro, Pamela
    Macrae, Erin Macrae
    Painter, Corrie
    Kryukov, Gregory
    Krop, Ian E.
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [38] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
    Modi, S.
    Jacot, W.
    Iwata, H.
    Park, Y. H.
    Vidal Losada, M. J.
    Li, W.
    Tsurutani, J.
    Zaman, K.
    Ueno, N. T.
    Prat, A.
    Papazisis, K.
    Rugo, H. S.
    Harbeck, N.
    Im, S-A.
    De Laurentiis, M.
    Orbegoso, C. M. A.
    Yung, L.
    Cheng, F-C.
    Cheng, Y.
    Cameron, D. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S334 - S335
  • [39] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
    Tsurutani, J.
    Jacot, W.
    Yamashita, T.
    Riaz, F.
    Yerushalmi, R.
    Im, S-A.
    Niikura, N.
    Halser-Strub, U.
    Cortes, J.
    Wennstig, A-K.
    Chae, Y.
    Wang, X.
    Li, W.
    Simon, H.
    Masci, G.
    Tamburini, E.
    Aguilar, C. Orbegoso
    Tecson, K.
    Yung, L.
    Modi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S342 - S343
  • [40] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Ueno, N. T.
    Jacot, W.
    Yamashita, T.
    Sohn, J.
    Tokunaga, E.
    Prat, A.
    Tsurutani, J.
    Park, Y. H.
    Rugo, H. S.
    Xu, B.
    Cardoso, F.
    Mitri, Z.
    Mahtani, R.
    Dunton, K.
    Wang, Y.
    Gambhire, D.
    Cottone, F.
    Harbeck, N.
    Cameron, D. A.
    Modi, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633
12345